Skip to content
Disclosery

OrbiMed Genesis GP LLC

Reporting owner on Forms 3, 4 and 5, CIK 1808744.

OrbiMed Genesis GP LLC reported on 1 issuer in 3 filings, the latest a 13D filed 2026-10-02.

Issuers

IssuerRoles in the latest filingFilingsLast filed
ADARx Pharmaceuticals, Inc. CIK 1802369director, 10% owner12026-09-30

Transactions and holdings

Every row of the person's Forms 3, 4 and 5, newest first, with the price and the amount owned after the row as filed.

SecurityDateCodeSharesPriceOwned afterFiling
ADARx Pharmaceuticals, Inc. Common Stock2026-09-28C converted+10,690,53010,690,530Form 4
ADARx Pharmaceuticals, Inc. Common Stock2026-09-28C converted+2,000,96212,691,492Form 4
ADARx Pharmaceuticals, Inc. Common Stock2026-09-28C converted+769,60113,461,093Form 4
ADARx Pharmaceuticals, Inc. Common Stock2026-09-28C converted+564,18714,025,280Form 4
ADARx Pharmaceuticals, Inc. Common Stock2026-09-28P bought+300,249$1714,325,529Form 4
ADARx Pharmaceuticals, Inc. Common Stock2026-09-28C converted+7,127,0197,127,019Form 4
ADARx Pharmaceuticals, Inc. Common Stock2026-09-28C converted+1,333,9758,460,994Form 4
ADARx Pharmaceuticals, Inc. Common Stock2026-09-28C converted+513,0678,974,061Form 4
ADARx Pharmaceuticals, Inc. Common Stock2026-09-28C converted+256,4489,230,509Form 4
ADARx Pharmaceuticals, Inc. Common Stock2026-09-28P bought+61,516$179,292,025Form 4
ADARx Pharmaceuticals, Inc. Common Stock2026-09-28P bought+588,235$17588,235Form 4
ADARx Pharmaceuticals, Inc. Series A Preferred Stock, derivative2026-09-28C converted-10,690,530$00Form 4
ADARx Pharmaceuticals, Inc. Series B Preferred Stock, derivative2026-09-28C converted-2,000,962$00Form 4
ADARx Pharmaceuticals, Inc. Series B-1 Preferred Stock, derivative2026-09-28C converted-769,601$00Form 4
ADARx Pharmaceuticals, Inc. Series C Preferred Stock, derivative2026-09-28C converted-564,187$00Form 4
ADARx Pharmaceuticals, Inc. Series A Preferred Stock, derivative2026-09-28C converted-7,127,019$00Form 4
ADARx Pharmaceuticals, Inc. Series B Preferred Stock, derivative2026-09-28C converted-1,333,975$00Form 4
ADARx Pharmaceuticals, Inc. Series B-1 Preferred Stock, derivative2026-09-28C converted-513,067$00Form 4
ADARx Pharmaceuticals, Inc. Series C Preferred Stock, derivative2026-09-28C converted-256,448$00Form 4

Filings

The person's Forms 3, 4 and 5, and any 13D or 13G naming it.

FilingSubjectFiledAcceptedIngested
13D 0000947871-26-000917 ADARX PHARMACEUTICALS INC2026-10-02
Form 4 0000947871-26-000910 ADARx Pharmaceuticals, Inc.2026-09-30
13D 0000947871-26-000898 ELECTRA THERAPEUTICS INC2026-09-25